IPOX® China Index (CNI)

The IPOX® China Index is an applied market cap-weighted index measuring the performance of the top 50 companies ranked quarterly in the IPOX® China Composite Index, subject to defined liquidity and exposure criteria. The IPOX® China Index has historically captured ca. 60% of total market cap created through New Listings by China-domiciled companies (non-A-shares) over the past four years, respectively.

  • Comprehensive Exposure: Captures nearly all significant IPO and spin-off activity in China (excluding A-shares) over the past four years, ensuring broad exposure to the new listings market.

  • Proprietary Index Technology: Utilizes IPOX®'s proven and proprietary index technology to select the 50 largest and most liquid recent IPOs and spin-offs from the IPOX® China Composite Index.

  • Market-Cap Weighting: Employs a market-cap weighting scheme with a 10% cap on all constituents to ensure diversified exposure across various sectors.

  • Quarterly Rebalancing: Rebalances on a quarterly basis to maintain focus on new listings and IPO M&A corporate actions.

The Chinese Market in Focus

China's consumer discretionary sector is well-represented in the IPOX® China Index, featuring companies like Tumi luggage maker Samsonite International SA, e-commerce giant PDD Holdings Inc, and Li Auto Inc. These firms showcase China's strength in innovative consumer products, electric vehicles and services.

The index also highlights China's dynamic technology and communication services sectors, including companies such as online gaming giant NetEase Inc and Taiwanese electronics manufacturing firm Pegatron Corp. These firms underscore the technological advancement and digital transformation within Greater China.

Beyond consumer discretionary and technology, the IPOX® China Index includes prominent companies from health care (Akeso Inc, SciClone Pharmaceuticals) and other sectors, reflecting the extensive range of industries in the Chinese economy and the variety of companies going public.

Contact info@ipox.com to learn more about licensing and sub-advisory opportunities to provide exposure to the most promising new listings in the Chinese market.